Still not sure your collective enthusiasm will be enough in this market. Phase 3 can disappoint let alone 2b.
One positive for me is that it's not a hot HC pick after spending so many weeks-months at the top. Expectations are realigning with market reality except for a few here it appears.
All this changes if they get the right trial results. The key is the 2 letter word in the previous sentence.
